June 5, 2017 Bio/Pharma/CRO PR/Corporate

Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer

Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more

June 1, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan

2017 2017/06/01 Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan Kusatsu/Shiga, Japan — Jun 1, 2017 — Takara Bio Inc. (Takara Bio) announced that the Clinical Trial Notification was submitted to PMDA (Pharmaceuticals and Medical Devices Agency; Japanese regulatory agency)... Read more

May 29, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan

2017 2017/05/29 First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan Kusatsu/Shiga, Japan — May 29, 2017 — Takara Bio Inc. (Takara Bio), today announced that the first patient with melanoma has been enrolled into Oncolytic Virus HF10(TBI-1401) phase II clinical trial in Japan on May 26, 2017. In this clinical study,... Read more

May 22, 2017 Acad, Gov/Utilities Atomic Spectroscopy Bio/Pharma/CRO Lab Top-10 Microscopy Product Launch

Bruker Launches the S8 TIGER™ Series 2 WDXRF System for Elemental Analysis in Industrial and Academic Research and Materials Quality Control

KARLSRUHE, Germany, May 22, 2017 /PRNewswire/ — Today Bruker announces the launch of its new S8 TIGER™ Series 2, the next-generation Wavelength Dispersive X-Ray Fluorescence (WDXRF) spectrometer. The S8 TIGER Series 2 is the most versatile WDXRF tool available for advanced quantitative elemental analysis in industrial and academic materials research, as well as in industrial quality... Read more

May 18, 2017 Bio/Pharma/CRO PR/Corporate

Roche presents the first Phase I efficacy and safety data on CEA-TCB (CEA CD3 TCB), a novel T-cell bispecific antibody targeting solid tumours

Basel, 18 May 2017 Roche presents the first Phase I efficacy and safety data on CEA-TCB (CEA CD3 TCB), a novel T-cell bispecific antibody targeting solid tumours Encouraging clinical activity in metastatic colorectal cancer after failure of at least two prior chemotherapy regimens to be presented at the ASCO Annual Meeting Roche (SIX: RO, ROG;... Read more

May 17, 2017 Bio/Pharma/CRO M&A, Partnerships Uncategorized

GE Healthcare’s FlexFactory to power Dr. Reddy’s biosimilar expansion plans

CHALFONT ST. GILES, UK and Bangalore, INDIA – 18 May 2017 – GE Healthcare today announced that Dr. Reddy’s Laboratories Limited will install India’s first-ever FlexFactory, a single-use manufacturing platform to expand the biologics production capacity at its facility in Hyderabad, India. FlexFactory will make Dr. Reddy’s biopharmaceutical manufacturing set-up more flexible and efficient, strengthening... Read more

May 16, 2017 Bio/Pharma/CRO Cell Analysis Tools Lab Top-10 M&A, Partnerships

MilliporeSigma’s CHOZN® Expression System Selected for Bi-specific Antibody Development by SystImmune

 Accelerates development timelines with faster, easier selection and scale up of clones  Delivers higher titers of recombinant proteins Billerica, Massachusetts, May 16, 2017 — MilliporeSigma today announced that its CHOZN® expression system will be used by SystImmune, a Seattle-based biotechnology company, for commercial development of a bi-specific antibody therapeutic. The CHOZN® expression system is designed... Read more